Clinical Trials
23 trialsNCT02755844 2026-05-27
ENDOLA
Hospices Civils de Lyon
Phase 1/2 Completed
NCT05383482 2025-11-17
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
Laekna Limited
Phase 1/2 Completed
NCT03126110 2025-08-14
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT03314935 2025-08-12
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
Incyte Corporation
Phase 1/2 Completed
NCT02611024 2025-07-09
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
Phase 1/2 Completed
NCT02632448 2025-05-02
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
Esperas Pharma Inc.
Phase 1/2 Completed
NCT03345485 2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2 Completed
NCT04570839 2024-07-18
COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.
Compugen Ltd
Phase 1/2 Completed
NCT04823065 2024-05-13
4FMFES-PET Imaging of Endometrial and Ovarian Cancers
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Phase 1/2 Completed
NCT03665285 2024-03-08
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.
Phase 1/2 Completed
NCT02988817 2023-08-01
Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors
Genmab
Phase 1/2 Completed
NCT03366480 2023-02-22
Endolung
Ability Pharmaceuticals SL
Phase 1/2 Completed
NCT03241173 2022-09-27
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT02178722 2022-02-14
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Incyte Corporation
Phase 1/2 Completed
NCT02001623 2021-12-29
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Seagen Inc.
Phase 1/2 Completed
NCT01631552 2021-08-12
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
Gilead Sciences
Phase 1/2 Completed
NCT02807844 2021-08-11
Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
Novartis
Phase 1/2 Completed
NCT02552121 2021-04-08
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Seagen Inc.
Phase 1/2 Completed
NCT00333502 2020-05-28
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
Lumos Pharma
Phase 1/2 Completed
NCT01580696 2020-05-04
Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer
San Antonio Military Medical Center
Phase 1/2 Completed
NCT00416455 2019-07-23
Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00006357 2012-09-24
STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1/2 Completed
NCT00032162 2012-05-31
Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer
AGO Study Group
Phase 1/2 Completed